Steve Wenglowsky

发表

Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process

Y. Ran, E. Choo, B. Alicke, 2011, Xenobiotica; the fate of foreign compounds in biological systems.

Biomimetic macrocycle-forming Diels-Alder reaction of an iminium dienophile: synthetic studies directed toward gymnodimine.

Steve Wenglowsky, Y. Kishi, J. Johannes, 2005, Organic letters.

Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.

E. Laird, S. Gloor, G. Vigers, 2014, Bioorganic & medicinal chemistry letters.

The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.

Tyler T. Risom, E. Laird, S. Gloor, 2012, Bioorganic & medicinal chemistry letters.

Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.

E. Laird, Y. Ran, G. Hatzivassiliou, 2012, Journal of medicinal chemistry.

The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.

E. Laird, B. Brandhuber, G. Vigers, 2011, Bioorganic & medicinal chemistry letters.

Non-oxime inhibitors of B-Raf(V600E) kinase.

E. Laird, B. Brandhuber, G. Vigers, 2011, Bioorganic & medicinal chemistry letters.

Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.

Bin Wang, G. Vigers, S. Seiwert, 2014, Journal of medicinal chemistry.

Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.

Tyler Risom, Zhaoyang Wen, Ignacio Aliagas, 2011, ACS medicinal chemistry letters.

An Asymmetric Synthesis of Optically Pure α,α-Disubstituted Amino Aldehydes, α,α-Disubstituted Amino Acids, and Sterically Demanding Dipeptides

Steve Wenglowsky, L. Hegedus, 1998 .

Three-Component Intramolecular Two-Alkyne Annulations of Fischer Carbene Complexes: New Strategies for Steroid Synthesis

Steve Wenglowsky, R. Ball, Jianming Bao, 1994 .

Pyrazolo[3,4-b]pyridine kinase inhibitors: a patent review (2008 – present)

Steve Wenglowsky, S. Wenglowsky, 2013, Expert opinion on therapeutic patents.

Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor.

Y. Ran, E. Choo, J. Boggs, 2013, International journal of pharmaceutics.

Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase.

Zhaoyang Wen, Joachim Rudolph, E. Laird, 2013, Bioorganic & medicinal chemistry letters.

Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.

Ellen R. Laird, Tyler Risom, Zhaoyang Wen, 2011, Bioorganic & medicinal chemistry letters.

Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.

Tyler T. Risom, E. Laird, S. Gloor, 2012, Bioorganic & medicinal chemistry letters.

Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing.

Y. Ran, S. Gloor, J. Rudolph, 2012, Bioorganic & medicinal chemistry letters.